Novo Nordisk's Pipeline Paradox: Better Numbers, Louder Doubts

Novo Nordisk beats Q2 estimates but shares lag as investors weigh Wegovy pill competition from Eli Lilly and pipeline concerns.

The arithmetic at Novo Nordisk has rarely looked so contradictory. Second-quarter results beat expectations, the full-year outlook was tightened to a less painful range, and the share price has still spent the past fortnight drifting sideways, caught between operational progress and a market that wants proof of future growth rather than reassurance about the present.

Chief executive Mike Doustdar is responding with a two-pronged push: accelerating internal research and pursuing so-called bolt-on acquisitions to fortify the product pipeline. The strategy was laid out to investors shortly after an upgraded 2026 guidance failed to spark the kind of rally the company might have hoped for.

A Guidance Upgrade That Landed Flat

The numbers themselves tell a story of genuine improvement. In the second quarter of 2026, adjusted revenue grew 7 percent at constant exchange rates, while adjusted operating profit climbed 11 percent. The adjusted operating result of 33.389 billion Danish kroner came in ahead of analyst expectations, according to Reuters. The company also refined its full-year forecast, narrowing the range for adjusted revenue and operating profit growth to 0 to minus 6 percent at constant currencies, an improvement on the previous minus 4 to minus 12 percent band.

Adjusted revenue for the quarter reached 78.5 billion kroner, but the picture was complicated by impairments of 6.3 billion kroner that dragged reported operating profit down 16 percent. That mixture of operational strength and balance-sheet charges helps explain why analyst reactions have been unusually split.

The share price has nonetheless moved higher since the results were published, gaining roughly 5.4 percent, though it remains some distance from where bulls would like it to be. At the latest close, the stock traded at 40.45 euros, barely above its 50-day average of 41.30 euros, and roughly 26 percent below its January 52-week high. The stock is down 9.7 percent since the start of the year.

The Competitive Question Hanging Over Everything

The central debate among analysts has crystallized around a single issue: can the Wegovy pill hold its ground against Eli Lilly's oral obesity franchise, or has the competitive balance already shifted? That question has become the lens through which nearly all recent data is being viewed.

Berenberg's decision on Wednesday to downgrade the stock from "Buy" to "Hold" captured the bearish camp's reasoning. The brokerage cut its price target to 47 US dollars, or 305 Danish kroner, citing intensifying competition from Eli Lilly in the oral weight-loss market and arguing that the Wegovy pill's upside potential was already largely reflected in the valuation.

The Wegovy pill generated 3.22 billion kroner in second-quarter sales, slightly below the 3.3 to 3.6 billion kroner analysts had penciled in. Meanwhile, the REDEFINE-4 trial program for the successor candidate CagriSema showed weight loss equivalent to tirzepatide but no superior blood sugar control — a result that does little to settle the differentiation debate.

Pipeline Setbacks and a Buyback in Motion

The skepticism predates the quarterly figures. Late July brought news that the ZEUS study for ziltivekimab had missed its primary goal of reducing major cardiovascular events compared with placebo, a setback for the company's efforts to diversify beyond diabetes and obesity. Since that study readout, the stock has shed 1.3 percent on balance, though it had fallen more sharply in between.

The impairment of 4.0 billion kroner on the weight-loss candidate monlunabant adds another layer of caution, a reminder that not every pipeline asset will make it to market.

Against that backdrop, management continues to signal confidence through its buyback program. The current mandate, expanded roughly two weeks ago, permits repurchases of B-shares worth up to 11,200,000,010.45 Danish kroner between May 6, 2026 and February 1, 2027. By August 7, nearly 27.9 million B-shares had been bought back at an average price of 279.01 kroner. Between August 4 and 7 alone, a further 820,000 B-shares were acquired. The program has run alongside a 10.5 percent decline in the share price since it was enlarged.

Diverging Analyst Views

The analyst community remains deeply divided. SB1 Markets raised its price target to 370 Danish kroner around a week ago and reaffirmed a buy recommendation. Citigroup and Landesbank Baden-Württemberg moved in the opposite direction, cutting their targets to 310 and 320 kroner respectively while maintaining neutral and hold ratings. Zacks Research, for its part, upgraded the stock from "Strong Sell" to "Hold" on Wednesday, suggesting some stabilization in expectations.

Reasons for Optimism

The bull case rests on several concrete developments. The European Medicines Agency's July approvals for the Wegovy pill, based on OASIS-4 data, and for the high-dose Wegovy 7.2 mg pen, based on STEP-UP data, open up additional market segments in Europe. The once-weekly basal insulin Awiqli is now available in the United States, strengthening the diabetes portfolio beyond the weight-loss franchise.

The company is also investing in a strategic partnership with Amazon Web Services aimed at accelerating drug discovery and clinical development through artificial intelligence, including a co-innovation hub at Novo's King's Cross site in London.

What to Watch

The near-term trajectory will likely be shaped by further analyst reactions to the recent study and quarterly data, as well as competitive developments in the oral weight-loss segment. The GLP-1 volume growth that underpins the raised guidance, combined with the new European approvals, keeps a recovery scenario intact. But if Eli Lilly's competitive pressure continues to build against the Wegovy pill, or if CagriSema fails to demonstrate clear differentiation in further analyses, the skepticism visible in Berenberg's downgrade could spread.

Whether Doustdar's push on research speed and bolt-on acquisitions can restore market confidence is a question that will only be answered over the coming quarters. For now, investors are weighing operational progress against competitive risk, and the verdict remains unresolved.